ADHD Clinical Trial Landscape
Data updated: May 20, 2026
331 clinical trials tracked since 2008
ADHD is being studied across 331 clinical trials registered since 2008, with 38 programs currently active. The competitive pipeline includes 9 active Phase 3 trials, 12 active Phase 2 trials, and 7 active Phase 1 trials. Top industry sponsors include Otsuka Pharmaceutical Co., Ltd., Boehringer Ingelheim, Bazelet Nehushtan LtD..
38 active
/
331 total (since 2008)
7
Phase 1 Active
46 total
12
Phase 2 Active
89 total
9
Phase 3 Active
117 total
16
Phase 4 Active
107 total
Top Industry Sponsors
Sorted by active Active Done Failed
Otsuka Pharmaceutical Co., Ltd. 4 0 0
Boehringer Ingelheim 1 0 0
Bazelet Nehushtan LtD. 1 0 0
Takeda 0 20 2
Supernus Pharmaceuticals, Inc. 0 14 4
+ 10 more sponsors — see full table below
Featured Phase 3 Trials
NCT07086313 RECRUITING
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
Otsuka Pharmaceutical Co., Ltd. n=315
NCT07087327 RECRUITING
A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
Otsuka Pharmaceutical Co., Ltd. n=180
NCT06931080 RECRUITING
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
Otsuka Pharmaceutical Co., Ltd. n=630
NCT06926829 RECRUITING
A Long-term Trial of EB-1020 in Adult Patients With ADHD
Otsuka Pharmaceutical Co., Ltd. n=180
+ 112 more Phase 3 trials — see full database below
ADHD — Trials Started by Year (last 10 years)
2016 18
2017 18
2018 20
2019 19
2020 10
2021 6
2022 5
2023 9
2024 14
2025 13
2026 6
TheraRadar.com
Full Trial Database
Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.
Top Sponsors (all-time)
Otsuka Pharmaceutical Co., Ltd. 4
Boehringer Ingelheim 1
Bazelet Nehushtan LtD. 1
Takeda 22
Supernus Pharmaceuticals, Inc. 18
Otsuka Pharmaceutical Development & Commercialization, Inc. 14
Eli Lilly 12
Sumitomo Pharma America, Inc. 11
Rhodes Pharmaceuticals, L.P. 8
Alcobra Ltd. 6
Active Trials by Phase
Phase 1 7
Phase 2 12
Phase 3 9
Phase 4 16
Enrollment Size Distribution
1-50 128
51-200 113
201-500 67
501-1k 9
1k+ 1
All Industry Sponsors
Sorted by active Active Done Failed
Otsuka Pharmaceutical Co., Ltd. 4 0 0
Boehringer Ingelheim 1 0 0
Bazelet Nehushtan LtD. 1 0 0
Takeda 0 20 2
Supernus Pharmaceuticals, Inc. 0 14 4
Otsuka Pharmaceutical Development & Commercialization, Inc. 0 13 1
Eli Lilly 0 9 3
Sumitomo Pharma America, Inc. 0 11 0
Rhodes Pharmaceuticals, L.P. 0 8 0
Alcobra Ltd. 0 5 1
Aevi Genomic Medicine, LLC, a Cerecor company 0 5 0
Tris Pharma, Inc. 0 5 0
Pfizer 0 2 3
Cingulate Therapeutics 0 3 1
Neurocentria, Inc. 0 1 2
NCT07086313 RECRUITING
A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
Otsuka Pharmaceutical Co., Ltd. n=315
NCT07087327 RECRUITING
A Long-term Trial of EB-1020 in Pediatric Patients With ADHD
Otsuka Pharmaceutical Co., Ltd. n=180
NCT06931080 RECRUITING
Evaluation of the Efficacy and Safety of EB-1020 in Adult ADHD Patients
Otsuka Pharmaceutical Co., Ltd. n=630
NCT06926829 RECRUITING
A Long-term Trial of EB-1020 in Adult Patients With ADHD
Otsuka Pharmaceutical Co., Ltd. n=180
NCT04704687 RECRUITING
Clinical Efficacy and Long Term Effects of Transcranial Direct Current Stimulation (tDCS) in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
Centre Hospitalier Universitaire, Amiens n=150
NCT04240756 ACTIVE NOT RECRUITING
Treating Parents with ADHD and Their Young Children Via Telehealth: a Hybrid Type I Effectiveness-Implementation Trial
University of Maryland, College Park n=240
NCT05832489 RECRUITING
EEG-MRI Imaging of Methylphenidate Effects in Adult ADHD and Attentional Symptoms in Mood Disorders
University Hospital, Strasbourg, France n=80
NCT06973577 COMPLETED
P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety
Otsuka Pharmaceutical Development & Commercialization, Inc. n=315
NCT05924594 SUSPENDED
Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
Cingulate Therapeutics n=45
NCT05386251 WITHDRAWN
Effectiveness of a Digital Strategy-based Educational Skills Group for Secondary Students With Organization and Academic Motivation Challenges
Seattle Children's Hospital
NCT05972044 COMPLETED
A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS)
Axsome Therapeutics, Inc. n=516
NCT05286762 COMPLETED
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
Cingulate Therapeutics n=103
NCT06215144 TERMINATED
Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD
Neurocentria, Inc. n=95
NCT06454604 COMPLETED
Virtual Reality Treatment for Emerging Adults With ADHD
Rutgers, The State University of New Jersey n=60
NCT06431256 TERMINATED
Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD
Ironshore Pharmaceuticals and Development, Inc n=26
NCT06854601 COMPLETED
Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12
Pharmasoft n=333
NCT05631626 COMPLETED
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
Cingulate Therapeutics n=21
NCT02348073 COMPLETED
Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy
Hospices Civils de Lyon n=77
NCT05683249 COMPLETED
Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD)
Neurocentria, Inc. n=223
NCT03605849 COMPLETED
A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. n=662
NCT03659929 COMPLETED
Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate
Arbor Pharmaceuticals, Inc. n=320
NCT01351272 COMPLETED
Genetic Modulation of Working Memory in Attention Deficit Hyperactivity Disorder (ADHD)
Wuerzburg University Hospital n=41
NCT04569357 COMPLETED
Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children
Materia Medica Holding n=363
NCT02691182 TERMINATED
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)
Supernus Pharmaceuticals, Inc. n=491
NCT03597503 TERMINATED
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
Supernus Pharmaceuticals, Inc. n=41
NCT02618434 COMPLETED
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
Supernus Pharmaceuticals, Inc. n=297
NCT04839562 COMPLETED
A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults
Massachusetts General Hospital n=66
NCT06006871 COMPLETED
Effectiveness of the Serious Video Game MOON in Emotional Regulation in ADHD
Puerta de Hierro University Hospital n=76
NCT02618408 COMPLETED
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
Supernus Pharmaceuticals, Inc. n=333
NCT03834766 COMPLETED
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD
Tris Pharma, Inc. n=130
NCT02502799 TERMINATED
Intervention for Teens With ADHD and Substance Use
Florida International University n=158
NCT01239030 COMPLETED
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
Rhodes Pharmaceuticals, L.P. n=230
NCT01269463 COMPLETED
Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting
Rhodes Pharmaceuticals, L.P. n=26
NCT04016779 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Supernus Pharmaceuticals, Inc. n=374
NCT03481959 TERMINATED
Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity
Assistance Publique - Hôpitaux de Paris n=3
NCT01883817 COMPLETED
Effect of Omega-3 Fatty Acid on Cortical Function in ADHD
University of Cincinnati n=30
NCT03605680 COMPLETED
A Trial Evaluating the Efficacy, Safety, & Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. n=604
NCT02704390 COMPLETED
Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
Orient Pharma Co., Ltd. n=64
NCT02450890 COMPLETED
Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
Orient Pharma Co., Ltd. n=114
NCT03605836 COMPLETED
A Trial to Evaluate the Efficacy, Safety, and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-deficit/Hyperactivity Disorder
Otsuka Pharmaceutical Development & Commercialization, Inc. n=590
NCT02777931 COMPLETED
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
Aevi Genomic Medicine, LLC, a Cerecor company n=101
NCT03618030 COMPLETED
PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Purdue Pharma, Canada n=288
NCT02520388 COMPLETED
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting
Ironshore Pharmaceuticals and Development, Inc n=163
NCT02493777 COMPLETED
A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting
Ironshore Pharmaceuticals and Development, Inc n=125
NCT03460652 COMPLETED
KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD
Zevra Therapeutics n=282
NCT03247543 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Children With ADHD
Supernus Pharmaceuticals, Inc. n=313
NCT03247556 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) High Dose in Adolescents With ADHD
Supernus Pharmaceuticals, Inc. n=297
NCT03247530 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
Supernus Pharmaceuticals, Inc. n=477
NCT01244490 COMPLETED
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Shire n=338
NCT03292952 COMPLETED
KP415 Classroom Study in Children (6-12 Years of Age) With ADHD
Zevra Therapeutics n=155
NCT02255513 COMPLETED
A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD
Ironshore Pharmaceuticals and Development, Inc n=43
NCT03247517 COMPLETED
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
Supernus Pharmaceuticals, Inc. n=310
NCT01500694 COMPLETED
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
Shire n=215
NCT00763971 COMPLETED
Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17
Shire n=336
NCT00735371 COMPLETED
Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Shire n=314
NCT00734578 COMPLETED
Efficacy and Safety of SPD503 in Combination With Psychostimulants
Shire n=461
NCT00697515 COMPLETED
Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Shire n=142
NCT00784654 COMPLETED
Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17
Shire n=276
NCT03260205 COMPLETED
Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)
Shire n=199
NCT03325894 TERMINATED
Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)
Shire n=141
NCT02604407 COMPLETED
Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)
Shire n=275
NCT02466425 COMPLETED
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)
Shire n=264
NCT01274221 WITHDRAWN
Safety and Efficacy of SPD489 in Adolescent Subjects Aged 13-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Shire
NCT03325881 COMPLETED
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
Shire n=89
NCT02466386 COMPLETED
Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder
Shire n=113
NCT02083783 COMPLETED
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Tris Pharma, Inc. n=108
NCT03231800 COMPLETED
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Sumitomo Pharma America, Inc. n=95
NCT02734693 COMPLETED
A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
Sumitomo Pharma America, Inc. n=132
NCT01796262 COMPLETED
The Effects of DHA on Attention Deficit and Hyperactivity Disorder
IRCCS Eugenio Medea n=50
NCT03172481 COMPLETED
PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
Purdue Pharma, Canada n=156
NCT00965419 TERMINATED
A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder
Eli Lilly and Company n=267
NCT04016792 WITHDRAWN
Classroom Study of SPN-812 in Children With ADHD
Supernus Pharmaceuticals, Inc.
NCT03088267 COMPLETED
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study
Tris Pharma, Inc. n=18
NCT02139124 COMPLETED
The Efficacy and Safety of PRC-063 in Adult ADHD Patients
Rhodes Pharmaceuticals, L.P. n=375
NCT03662763 COMPLETED
Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity
Maastricht University Medical Center n=12
NCT00723190 COMPLETED
Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)
Shionogi n=303
NCT01835548 COMPLETED
NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Neos Therapeutics, Inc n=87
NCT01853280 COMPLETED
L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults
Massachusetts General Hospital n=47
NCT00857220 COMPLETED
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
Sumitomo Pharma America, Inc. n=304
NCT01340690 TERMINATED
Efficacy Study of Polyunsaturated Fatty Acids in Children and Adolescents With Attention Deficit/ Hyperactivity Disorder
Johannes Gutenberg University Mainz n=284
NCT01109849 COMPLETED
Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth
Florida International University n=230
NCT01000064 TERMINATED
Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits
Vanderbilt University n=22
NCT02160262 COMPLETED
Open-label Safety Study in Adults With ADHD
Sumitomo Pharma America, Inc. n=724
NCT01344044 COMPLETED
Brain-Computer Interface (BCI) Based Intervention for Attention Deficit Hyperactivity Disorder (ADHD)
National Healthcare Group, Singapore n=192
NCT02059642 COMPLETED
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
Alcobra Ltd. n=300
NCT02477748 TERMINATED
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
Alcobra Ltd. n=283
NCT02555150 COMPLETED
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
Rhodes Pharmaceuticals, L.P. n=40
NCT01654250 COMPLETED
NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)
Pfizer n=90
NCT01022229 COMPLETED
The Safety and Efficacy of a Compound Natural Health Product in Children With Attention Deficit Hyperactivity Disorder (ADHD)
The Canadian College of Naturopathic Medicine n=16
NCT01363544 COMPLETED
Train Your Brain and Exercise Your Heart? Advancing the Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
R. van Mourik n=112
NCT00704990 COMPLETED
Combination Natural Health Product in Children With Attention Deficit/Hyperactivity Disorder (ADHD)
Kieran Cooley n=28
NCT02168127 COMPLETED
Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD
Rhodes Pharmaceuticals, L.P. n=360
NCT01777048 TERMINATED
Omega-3 Fatty Acids Supplementation in ADHD
University Hospital, Basel, Switzerland n=8
NCT01675804 COMPLETED
Computer-assisted Cognitive Rehabilitation (CACR), Placebo CACR and Psycho-stimulants in the Treatment of ADHD
Allameh Tabatabai University n=34
NCT00922636 COMPLETED
A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder
Eli Lilly and Company n=340
NCT00904670 COMPLETED
Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Pfizer n=45
NCT00700427 COMPLETED
A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Eli Lilly and Company n=2,017
NCT00782080 COMPLETED
Efficacy and Safety of St. John´s Wort/Valerian Extract Versus Placebo in Children and Adolescents With ADHD
Prof. Huss n=155
NCT00856973 COMPLETED
Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia
Sumitomo Pharma America, Inc. n=486
NCT01855984 COMPLETED
Tocotrienols for School-going Children With ADHD
RCSI & UCD Malaysia Campus n=160
NCT00969618 COMPLETED
A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
Eli Lilly and Company n=211
NCT01738334 COMPLETED
Effects Of The Mindfulness Meditation Practices On Cognition
Federal University of São Paulo n=40
NCT00962104 COMPLETED
Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
Eli Lilly and Company n=391
NCT00641329 COMPLETED
CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD
Addrenex Pharmaceuticals, Inc. n=198
NCT00730249 COMPLETED
Quality Assurance of Administering Methylphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD) - QUMEA
Medice Arzneimittel Pütter GmbH & Co KG n=150
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only